🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Matthias Pinter

University of Vienna

ORCID: 0000-0002-7260-532X

Also affiliated with Medical University of Vienna

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study”.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European Journal of Cancer(2022)10.1016/j.ejca.2022.08.024
N/A
0DataRank · unranked
112 citations

Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron +32 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302
N/A
0DataRank · unranked
11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

JHEP Reports(2024)10.1016/j.jhepr.2024.101295
N/A
0DataRank · unranked
9 citations

Philipp Mildenberger, Jennifer Gile, Fabian Jost‐Brinkmann, Bernhard Scheiner, Catherine Leyh +54 more

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

JHEP Reports(2025)10.1016/j.jhepr.2025.101685
N/A
0DataRank · unranked
2 citations

Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li +36 more